Packard, Chris J.

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

Vallejo-Vaz, A. J., Robertson, M., Catapano, A. L., Watts, G. F., Kastelein, J. J., Packard, C. J., Ford, I., & Ray, K. K. (2017) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 185

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

Björnson, E., Adiels, M., Taskinen, M.-R., Burgess, S., Rawshani, A., Borén, J., & Packard, C. J. (2023) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 183

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 160

Effect of pravastatin in people with diabetes and chronic kidney disease

Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 159

Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Demant, T., Bedford, D., Packard, C. J., & Shepherd, J. (1991) · Journal of Clinical Investigation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 145

Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort

Shiels, P. G., McGlynn, L. M., MacIntyre, A., Johnson, P. C. D., Batty, G. D., Burns, H., Cavanagh, J., Deans, K. A., Ford, I., McConnachie, A., et al. (2011) · PLoS ONE

Telomeres, Telomerase, and SenescenceHealth disparities and outcomes

Cited by 143

Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men

Gill, J. M. R., Al-Mamari, A., Ferrell, W. R., Cleland, S. J., Packard, C. J., Sattar, N., Petrie, J. R., & Caslake, M. J. (2004) · Journal of the American College of Cardiology

Cardiovascular and exercise physiologyDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 142

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Unraveling the directional link between adiposity and inflammation: A bidirectional Mendelian randomization approach

Welsh, P., Polisecki, E., Robertson, M., Jahn, S., Buckley, B. M., de Craen, A. J. M., Ford, I., Jukema, J. W., Macfarlane, P. W., Packard, C. J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism

Adipokines, Inflammation, and Metabolic DiseasesGenetic Associations and Epidemiology

Cited by 140

Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease

Packard, C. J. (2006) · Current Opinion in Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study

Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsLiver Disease Diagnosis and Treatment

Cited by 127

Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 121

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 104

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., et al. (2010) · Circulation

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 104

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias

Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 99

Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil

Olano-Martin, E., Anil, E., Caslake, M. J., Packard, C. J., Bedford, D., Stewart, G., Peiris, D., Williams, C. M., & Minihane, A. M. (2010) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 83

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans

Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight

Lipid metabolism and disordersLiver Disease Diagnosis and Treatment

Cited by 81

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates

Forster, L. F., Stewart, G., Bedford, D., Stewart, J. P., Rogers, E., Shepherd, J., Packard, C. J., & Caslake, M. J. (2002) · Atherosclerosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 77

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 57

Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia

Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 55

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics

Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Sihlbom, C., Thorsell, A., Zhou, H., et al. (2019) · Journal of Internal Medicine

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 54

Personality, Socio-Economic Status and Inflammation: Cross-Sectional, Population-Based Study

Millar, K., Lloyd, S. M., McLean, J. S., Batty, G. D., Burns, H., Cavanagh, J., Deans, K. A., Ford, I., McConnachie, A., McGinty, A., et al. (2013) · PLoS ONE

Health disparities and outcomesTryptophan and brain disorders

Cited by 47

Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes

Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 40